{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014654","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.879206+00:00","generated_at":"2026-05-15T07:55:49.445798+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off","bullets":["Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).","Thyroid revenue +14% YoY in Q4, +21% for FY; thyroid volume +11% Q4, +13% FY.","Debt fully paid off in Q4 2025; cash availability up $4.3M YoY.","Adjusted EBITDA Q4 $1.7M, FY $5.4M; company reiterates ~16% thyroid revenue growth guidance for 2026.","Business metrics improved: avg revenue/test +5%, DSO -19%, turnaround time -20%, accounts +9%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014654","json":"https://secwatch.observer/filing/0001493152-26-014654.json","markdown":"https://secwatch.observer/filing/0001493152-26-014654.md","text":"https://secwatch.observer/filing/0001493152-26-014654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/0001493152-26-014654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:55:49.445798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fbe724804e4d4881b7ddc618e1aba5f886320fe8","claim":"INTERPACE BIOSCIENCES, INC. reported fourth quarter and fiscal year ended December 31, 2025 results: revenue $9.2 million and $38.7 million, respectively, net income $22.8 million and $25.0 million, respectively.","evidence_excerpt":"stated in such filing. --- EX-99.1 (EX-99.1) --- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results ● Q4 and FY Revenue of $9.2 million and $38.7 million ● Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) ●","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226014654/0001493152-26-014654-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2025"},{"label":"Revenue","value":"$9.2 million and $38.7 million, respectively"},{"label":"Net income","value":"$22.8 million and $25.0 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}